Burning Rock Biotech (BNR) Receivables (2019 - 2026)

Burning Rock Biotech's Receivables history runs 8 years deep, the most recent figure standing at $25.7 million for Q1 2026.

• In Q1 2026, Receivables rose 5.54% year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at $25.7 million (up 5.54% YoY), while the FY2025 annual figure was $34.0 million, up 17.22% from the prior year.
• Receivables for Q1 2026 stood at $25.7 million, roughly flat from $25.6 million in the prior quarter.
• The five-year high for Receivables was $53.8 million in Q2 2022, with the low at $20.8 million in Q4 2023.
• The 5-year median for Receivables is $25.4 million (2023), against an average of $26.3 million.
• The sharpest annual moves came in 2022 and 2023: Receivables jumped 341.35% in 2022, then sank 48.23% in 2023.
• Burning Rock Biotech's Receivables stood at $21.3 million in 2022, then decreased by 2.59% to $20.8 million in 2023, then climbed by 11.13% to $23.1 million in 2024, then climbed by 11.07% to $25.6 million in 2025, then advanced by 0.16% to $25.7 million in 2026.
• Business Quant data shows BNR's Receivables at $25.7 million in Q1 2026, $25.6 million in Q4 2025, and $27.7 million in Q3 2025.